{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T18:37:05Z","timestamp":1767811025078,"version":"3.49.0"},"reference-count":47,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJNPH"],"accepted":{"date-parts":[[2025,7,11]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder that leads to increasing muscle weakening and early death. Steroids, the standard treatment of choice in slowing down disease progression, are plagued with adverse effects. Anti-inflammatory, antifibrotic effects and enhancement of muscle regeneration biomarkers after oral consumption of\n                      <jats:italic>Aureobasidium pullulans<\/jats:italic>\n                      strain N-163-produced beta 1,3\u20131,6-glucan (Neu REFIX) having been demonstrated in clinical and preclinical studies of DMD; in this study, we have investigated the effects on the gut microbiome in patients with DMD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Twenty-seven patients with DMD were included in the study (control (n=9), N-163 (n=18)). Whole-genome metagenomic sequencing was performed in pre-N-163 and post-N-163 intervention faecal samples of each of these participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After N-163 beta-glucan administration, the constitution of the gut microbiome in all the participants was modified to one with positive outcomes on health. There was an increase in butyrate-producing species such as\n                      <jats:italic>Roseburia<\/jats:italic>\n                      and\n                      <jats:italic>Faecalibacterium prausnitzii<\/jats:italic>\n                      . There was a decrease in harmful bacteria associated with inflammation such as enterobacteria and\n                      <jats:italic>Alistipes<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Beneficial reconstitution of the gut microbiome after Neu REFIX beta-glucan administration and its safety have been confirmed. These outcomes correlating with the anti-inflammatory, anti-fibrotic effects along with increase in dystrophin in skeletal muscle and plasma, reported earlier make us recommend further in-depth exploration on its role in epigenetic manipulation which when found encouraging might help other genetic diseases as well.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>CTRI\/2021\/05\/033346.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjnph-2023-000776","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:55:14Z","timestamp":1753462514000},"page":"432-440","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation"],"prefix":"10.1136","volume":"8","author":[{"given":"Kadalraja","family":"Raghavan","sequence":"first","affiliation":[{"name":"Department of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for Advanced Recovery and Education (JAICARE), Madurai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidyasagar Devaprasad","family":"Dedeepiya","sequence":"additional","affiliation":[{"name":"Nichi-In Centre for Regenerative Medicine, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine, Shinjuku-ku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobunao","family":"Ikewaki","sequence":"additional","affiliation":[{"name":"Department of Medical Life Science, Kyushu University of Health and Welfare, Nobeoka, Japan"},{"name":"Junsei Educational Institute, Nobeoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"University of Yamanashi Faculty of Medicine Graduate School of Medicine, Chuo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwamed","family":"Dinassing","sequence":"additional","affiliation":[{"name":"Ministry of Health and Wellness, Port Louis, Mauritius"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajappa","family":"Senthilkumar","sequence":"additional","affiliation":[{"name":"GN Corporation Co Ltd, Kofu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilkumar","family":"Preethy","sequence":"additional","affiliation":[{"name":"Nichi-In Centre for Regenerative Medicine, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-2687","authenticated-orcid":false,"given":"Samuel J K","family":"Abraham","sequence":"additional","affiliation":[{"name":"University of Yamanashi Faculty of Medicine Graduate School of Medicine, Chuo, Japan"},{"name":"GN Corporation Co Ltd, Kofu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2026010709451996000_8.2.432.1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"2026010709451996000_8.2.432.2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3990"},{"key":"2026010709451996000_8.2.432.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00036-X"},{"key":"2026010709451996000_8.2.432.4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"2026010709451996000_8.2.432.5","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1271872"},{"key":"2026010709451996000_8.2.432.6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3233\/JND-221540","article-title":"Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives","volume":"9","author":"Landfeldt","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"2026010709451996000_8.2.432.7","unstructured":"FDA . Elevidys approval update. 2024. Available: https:\/\/www.fda.gov"},{"key":"2026010709451996000_8.2.432.8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged \u22654 to <8\u2009Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"2026010709451996000_8.2.432.9","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213604","article-title":"Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee","volume":"104","author":"Oskoui","year":"2025","journal-title":"Neurology (ECronicon)"},{"key":"2026010709451996000_8.2.432.10","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213776","article-title":"Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy: The Ethics and Financial Toxicity of Exuberant Hope","volume":"104","author":"Smith","year":"2025","journal-title":"Neurology (ECronicon)"},{"key":"2026010709451996000_8.2.432.11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2024.2776","article-title":"Spending on Targeted Therapies for Duchenne Muscular Dystrophy","volume":"331","author":"Bendicksen","year":"2024","journal-title":"JAMA"},{"key":"2026010709451996000_8.2.432.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03304-z"},{"key":"2026010709451996000_8.2.432.13","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2025.1569289","article-title":"Improving the therapeutic efficacy of gene therapy for duchenne muscular dystrophy (DMD) by evaluating and managing inflammation","volume":"16","author":"Raghavan","year":"2025","journal-title":"Front Genet"},{"key":"2026010709451996000_8.2.432.14","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100800","article-title":"CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"2026010709451996000_8.2.432.15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326789"},{"key":"2026010709451996000_8.2.432.16","doi-asserted-by":"crossref","DOI":"10.1177\/1178638820980490","article-title":"Interactions between gut microbiota and skeletal muscle","volume":"13","author":"Gizard","year":"2020","journal-title":"Nutr Metab Insights"},{"key":"2026010709451996000_8.2.432.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112243"},{"key":"2026010709451996000_8.2.432.18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clicom.2021.11.001","article-title":"Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats","volume":"1","author":"Ikewaki","year":"2021","journal-title":"Clin Immunol Commun"},{"key":"2026010709451996000_8.2.432.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.06.008"},{"key":"2026010709451996000_8.2.432.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000203","article-title":"Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study","volume":"4","author":"Raghavan","year":"2022","journal-title":"BMJ Neurol Open"},{"key":"2026010709451996000_8.2.432.21","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.3233\/JAD-220388","article-title":"Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases","volume":"94","author":"Raghavan","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"2026010709451996000_8.2.432.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-000985","article-title":"Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease","volume":"9","author":"Preethy","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"2026010709451996000_8.2.432.23","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216225","article-title":"Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy","volume":"15","author":"Kalkan","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026010709451996000_8.2.432.24","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216244","article-title":"Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin-deficient mice","volume":"15","author":"Farini","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026010709451996000_8.2.432.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2023.06.007"},{"key":"2026010709451996000_8.2.432.26","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010709451996000_8.2.432.27","doi-asserted-by":"crossref","unstructured":"Dedeepiya VD , Vetrievel C , Ikewaki N , et al . Beneficial changes in the gut microbiome of patients with multiple sclerosis after consumption of neu-refix b-glucan in a clinical trial. medRxiv [Preprint] 2023. doi:10.1101\/2023.09.07.23295172","DOI":"10.1101\/2023.09.07.23295172"},{"key":"2026010709451996000_8.2.432.28","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.01226","article-title":"Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic","volume":"8","author":"Mart\u00edn","year":"2017","journal-title":"Front Microbiol"},{"key":"2026010709451996000_8.2.432.29","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9040697","article-title":"The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases","volume":"9","author":"Baldelli","year":"2021","journal-title":"Microorganisms"},{"key":"2026010709451996000_8.2.432.30","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0130"},{"key":"2026010709451996000_8.2.432.31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27105"},{"key":"2026010709451996000_8.2.432.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.03.022"},{"key":"2026010709451996000_8.2.432.33","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1038\/s41598-025-92258-4","article-title":"Enhanced expression of dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including diaphragm of mdx mice after oral administration of Neu REFIX beta 1,3-1,6 glucan","volume":"15","author":"Preethy","year":"2025","journal-title":"Sci Rep"},{"key":"2026010709451996000_8.2.432.34","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012063","article-title":"Trans-generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy","volume":"12","author":"Martone","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2026010709451996000_8.2.432.35","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.01329","article-title":"The Epigenetic Connection Between the Gut Microbiome in Obesity and Diabetes","volume":"10","author":"Sharma","year":"2019","journal-title":"Front Genet"},{"key":"2026010709451996000_8.2.432.36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1139\/gen-2020-0136","article-title":"Gut microbiome-mediated epigenetic regulation of brain disorder and application of machine learning for multi-omics data analysis","volume":"64","author":"Kaur","year":"2021","journal-title":"Genome"},{"key":"2026010709451996000_8.2.432.37","unstructured":"Venugopal V , Pavlakis S . Duchenne muscular dystrophy. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2025. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482346\/"},{"key":"2026010709451996000_8.2.432.38","doi-asserted-by":"crossref","first-page":"112123","DOI":"10.1016\/j.isci.2025.112123","article-title":"Stress-induced fetal programming contributes to the manifestation of Duchenne muscular dystrophy in mdx mice","volume":"28","author":"Gharibi","year":"2025","journal-title":"iScience"},{"key":"2026010709451996000_8.2.432.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107634","article-title":"\u03b2-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1","volume":"31","author":"Moorlag","year":"2020","journal-title":"Cell Rep"},{"key":"2026010709451996000_8.2.432.40","doi-asserted-by":"crossref","first-page":"00108","DOI":"10.15406\/ogij.2016.04.00108","article-title":"The Importance of Gut Microbiota in Pregnancy: Prevention, Care and Support","volume":"4","author":"Yedid","year":"2016","journal-title":"OGIJ"},{"key":"2026010709451996000_8.2.432.41","doi-asserted-by":"crossref","unstructured":"Raghavan K , Sivakumar T , Bharatidasan SS , et al . Efficacy of N-163 strain of Aureobasidium pullulans-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; results of a 6-month non-randomised open-label linear clinical trial. medRxiv 2023. doi:10.1101\/2023.04.29.23289260","DOI":"10.1101\/2023.04.29.23289260"},{"key":"2026010709451996000_8.2.432.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44330-0","article-title":"Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced \u03b2-glucan","volume":"13","author":"Preethy","year":"2023","journal-title":"Sci Rep"},{"key":"2026010709451996000_8.2.432.43","unstructured":"Abraham S , Aoki Y , Minegishi K , et al . Decline in muscle fatigue score of mdx mice after oral administration of neu-refix beta 1,3-1,6 glucans in a short duration study of 45 days. MDA Conference, USA; 2024"},{"key":"2026010709451996000_8.2.432.44","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-023-01483-y","article-title":"Association between blood eosinophil count and Duchenne muscular dystrophy severity and prognosis: a retrospective cohort study","volume":"49","author":"Jiang","year":"2023","journal-title":"Ital J Pediatr"},{"key":"2026010709451996000_8.2.432.45","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101366","article-title":"Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration","volume":"9","author":"Tulangekar","year":"2021","journal-title":"Biomedicines"},{"key":"2026010709451996000_8.2.432.46","unstructured":"MacNeil J , Jeyaraj L , Tsukada A , et al . Neutrophil to Lymphocyte Ratio (NLR) modifying b-glucan adjuvants ameliorating cytokine storm and Cancer burden, Hold Potential in sepsis management. Critical care canada forum (CCCF). Toronto, Canada, 2024."},{"key":"2026010709451996000_8.2.432.47","doi-asserted-by":"crossref","first-page":"1538147","DOI":"10.3389\/fimmu.2025.1538147","article-title":"Significance of neutrophil to lymphocyte ratio (NLR) and gut microbiome of astronauts during space missions and suggestions for beneficial modulations using novel beta-glucans","volume":"16","author":"Ikewaki","year":"2025","journal-title":"Front Immunol"}],"container-title":["BMJ Nutrition, Prevention &amp; Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjnph-2023-000776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T17:45:32Z","timestamp":1767807932000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutrition.bmj.com\/lookup\/doi\/10.1136\/bmjnph-2023-000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjnph-2023-000776"],"URL":"https:\/\/doi.org\/10.1136\/bmjnph-2023-000776","relation":{},"ISSN":["2516-5542"],"issn-type":[{"value":"2516-5542","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}